CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Yervoy for First Line Advanced Melanoma - Details

Project Number PC0042-000
Brand Name Yervoy
Generic Name Ipilimumab
Strength 5mg/mL
Tumour Type Skin and Melanoma
Indication First Line Advanced Melanoma
Funding Request For the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma
Review Status Complete
Pre Noc Submission Yes
NOC Date September 10, 2014
Manufacturer Bristol-Myers Squibb Canada
Sponsor Bristol-Myers Squibb Canada
Submission Date August 15, 2014
Submission Deemed Complete August 22, 2014
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ August 29, 2014
Check-point meeting October 6, 2014
pERC Meeting November 20, 2014
Initial Recommendation Issued December 4, 2014
Feedback Deadline ‡ December 18, 2014
Final Recommendation Issued December 22, 2014
Notification to Implement Issued January 14, 2015
Therapeutic Area First Line Advanced Melanoma
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.